Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 5,141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Los Angeles, California • Pasadena, California • San Jose, California + 10 more

Conditions: HIV Infections
Interventions: Interleukin-2; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV
Interventions: Lenacapavir long-acting, Standard of Care (SOC); Drug · Other
Lead sponsor: Kelley-Ross & Associates, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions: Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy; Behavioral · Device · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: CH505M5 N197D mRNA-gp160, CH505 TF mRNA-gp160; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Optimune oral nutritional supplement; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: AIDS, HIV Infections
Interventions: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART; Other · Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 29
States / cities: Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more

Conditions: HIV, Sleep, Smoking Cessation, Cardiovascular Diseases
Interventions: Varenicline, Smoking Cessation Counseling, Health Approach 1 to Reduce Smoking, Health Approach 2 to Reduce Smoking; Drug · Behavioral · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Tucson, Arizona

Conditions: HIV/AIDS, Methamphetamine Abuse, Depression
Interventions: MoodGym; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PrEP, HIV, Incarceration
Interventions: Multicomponent strategy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, HIV Infection
Interventions: Brentuximab Vedotin, Dacarbazine, Doxorubicin Hydrochloride, Pharmacological Study, Vinblastine; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Herpes Virus-Related Illnesses
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hiv, Sleep
Interventions: HIIT, CME; Behavioral
Lead sponsor: Christine Horvat Davey; Other
Eligibility: 50 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Cleveland, Ohio • Seattle, Washington

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Flucytosine, Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more

Conditions: HIV-1-infection
Interventions: 18F-Raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Dolutegravir Sodium Monohydrate, Ibalizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 579 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoma
Interventions: cilengitide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 3
States / cities: La Jolla, California • San Francisco, California • Nashville, Tennessee

Conditions: HIV Infections
Interventions: gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 46
States / cities: Montgomery, Alabama • Long Beach, California • Los Angeles, California + 34 more

Conditions: HIV Infections
Interventions: TBC-3B Vaccine, Smallpox Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1996
U.S. locations: 5
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more

Conditions: HIV/STI Incidence, Communication About Health Information
Interventions: The Gender Inclusive Sexuality Talks Program, GIST Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 12 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anal High Grade Squamous Intraepithelial Lesion
Interventions: mHRME (Mobile High resolution microendoscope), Proflavine Hemisulfate, High resolution anoscopy; Diagnostic Test · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: New York, New York • Houston, Texas

Conditions: HIV Infections
Interventions: Medroxyprogesterone acetate, Estradiol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rockville, Maryland

Search by objective public record fields.

A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

CSP #512 - Options in Management With Anti-Retrovirals

Wellness Intervention for Smoking and HIV

Depression Intervention Among Gay and Bisexual Men Receiving Treatment for Methamphetamine Use

HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

Relationship of Exercise, Sleep, and Inflammation Markers in People Living With HIV

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

Pharmacokinetics Distribution of Raltegravir by PET/MR

Compassionate Use of Ibalizumab for the Treatment of HIV Infection

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

The Gender Inclusive Sexuality Talks Program

The Effectiveness of High Resolution Microendoscopy for People Living With HIV

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women